UCB has struck a deal to acquire Candid Therapeutics for $2 billion upfront, hijacking a planned reverse merger with Rallybio ...

A phase 3 trial of Celcuity’s pan-PI3K/mTOR inhibitor has hit its primary endpoint, clearing the biotech to file a second ...

Ever since psychedelic medicine in the U.S. was stymied by government action, the field has been steadily clawing its way ...

Amgen has pulled the plug on midstage drug candidates for cancer and the autoimmune disease Sjögren’s syndrome, terminating ...

The FDA today announced a new initiative to allow its reviewers to access information from clinical trials in real time, with ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) on Thursday voted 6 to 3 that AstraZeneca has not demonstrated its oral ...

GSK and Alector have stopped a phase 2 trial of their Alzheimer’s disease drug candidate after an interim analysis found the ...

As the calendar turned from April to May, a big change came to the FDA. | Katherine Szarama, Ph.D., will take over as CBER ...

The FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer drugs camizestrant and Truqap ahead ...

Danish dermatology specialist Leo Pharma is paying $50 million for U.S. gene writing biotech Replay and its preclinical gene ...

Incyte’s povorcitinib has scored a pair of phase 3 wins for a skin condition, although analysts noted the oral JAK inhibitor ...

Theranostics is reshaping cancer care, but scaling it requires more than scientific innovation. In this episode of The Top ...